Synthesis and biological activities of topoisomerase I inhibitors, 6-arylmethylamino analogues of edotecarin

Journal of Medicinal Chemistry

Volumn 52, Issue 10, 2009, Pages 3225-3237

  Sunami, Satoshi ^a   Nishimura, Teruyuki ^a   Nishimura, Ikuko ^a   Ito, Satoru ^a   Arakawa, Hiroharu ^a   Ohkubo, Mitsuru ^a  

^a BANYU PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2,10 DIHYDROXY 6 [((3 HYDROXYMETHYL)PYRIDIN 4 YL)METHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [((4 HYDROXYMETHYL)PYRIDIN 3 YL)METHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [((6 HYDROXYMETHYL)PYRIDIN 2 YL)METHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(1H PYRROLO 2 YLMETHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(3 (HYDROXYMETHYL)BENZYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(3 HYDROXYBENZYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(4 (HYDROXYMETHYL)BENZYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(4 BROMOBENZYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(4 CYANOBENZYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(4 METHYLBENZYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(4 NITROBENZYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(PYRIDIN 2 YLMETHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(PYRIDIN 3 YLMETHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(PYRIDIN 4 YLMETHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(QUINOLIN 2 YLMETHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(QUINOLIN 3 YLMETHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 2,10 DIHYDROXY 6 [(QUINOLIN 4 YLMETHYL)AMINO] 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 6 (BENZYLAMINO) 2,10 DIHYDROXY 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A] PYRROLO [3,4 C] CARBAZOLE 5,7 (6H) DIONE; 6 [(2 FURYLMETHYL)AMINO] 2,10 DIHYDROXY 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 6 [(3 FURYLMETHYL)AMINO] 2,10 DIHYDROXY 13 (BETA DEXTRO GLUCOPYRANOSYL) 12,13 DIHYDRO 5H INDOLO [2,3 A]PYRROLO [3,4 C]CARBAZOLE 5,7 (6H) DIONE; 6 ARYLMETHYLAMINO ANALOGUE A; DNA TOPOISOMERASE INHIBITOR; EDOTECARIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STOMACH CANCER; TUMOR XENOGRAFT;

AMINES; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CARBAZOLES; CELL LINE, TUMOR; DNA TOPOISOMERASES, TYPE I; ENZYME INHIBITORS; FEMALE; HUMANS; HYDROCARBONS, AROMATIC; MICE; PYRIDINES; STOMACH NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66249113962     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm801641t     Document Type: Article

References (69)

1. Rothenberg, M. L. Topoisomerase I inhibitors: review and update. Ann. Oncol. 1997, 8, 837-855.
2. Beretta, G. L.; Perego, P.; Zunino, F. Targeting topoisomerase I: molecular mechanisms and cellular determinants of responce to topoisomerase I inhibitors. Expert Opin. Ther. Targets 2008, 12, 1243-1256.
3. Teicher, B. A. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. Biochem. Pharmacol. 2008, 75, 1262-1271.
4. Pommier, Y. Topoisomerase I inhibitors: camptothecins and beyond. Nat. Rev. Cancer 2006, 6, 789-802.
5. Potmesil, M. Camptothecin: from the bench research to the hospital wards. Cancer Res. 1994, 54, 1431-1439. (Pubitemid 24106402)
6. Wall, M. E.; Wani, M. C. Camptothecin and taxol: discovery to clinicsthirteenth Bruce F. Cain memorial award lecture. Cancer Res. 1995, 55, 753-760.
7. Goldwasser, F.; Bae, I.; Valenti, M.; Torres, K.; Pommier, Y. Topoisomerase I-related parameters and camptothecin activity in the colon carcinoma cell lines from the National Cancer Research Institute anticancer screen. Cancer Res. 1995, 55, 2116-2121.
8. Oberlies, N. H.; Kroll, D. Camptothecin and taxol: historic achievements in natural products research. J. Nat. Prod. 2004, 67, 127-135.
9. Pizzolato, J. F.; Saltz, L. B. The camptothecins. Lancet 2003, 361, 2235-2242.
10. Douillard, J. Y.; Cunningham, D.; Roth, A. D.; Navarro, M.; James, R. D.; Karasek, P.; Jandik, P.; Iveson, T.; Carmichael, J.; Alakl, M.; Gruia, G.; Awad, L.; Rougier, P. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000, 355, 1041-1047. (Pubitemid 30162806)
11. Cunningham, D.; Pyrhonen, S.; James, R. D.; Punt, C. J. A.; Hickish, T. F.; Heikkila, R.; Johannesen, T. B.; Starkhammar, H.; Topham, C. A.; Awad, L.; Jacques, C.; Herait, P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998, 352, 1413-1418. (Pubitemid 28510874)
12. Saltz, L. B.; Cox, J. V.; Blanke, C.; Rosen, L. S.; Fehrenbacher, L.; Moore, M. J.; Maroun, J. A.; Ackland, S. P.; Locker, P. K.; Pirotta, N.; Elfring, G. L.; Miller, L. L. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 2000, 343, 905-914.
13. Noda, K.; Nishiwaki, N.; Kawahara, M.; Negoro, S.; Sugiura, T.; Yokoyama, A.; Fukuoka, M.; Mori, K.; Watanabe, K.; Tamura, T.; Yamamoto, S.; saijo, N. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N. Engl. J. Med 2002, 346, 85-91.
14. Enzinger, P. C.; Kulke, M. H.; Clark, J. W.; Ryan, D. P.; Kim, H.; Earle, C. C.; Vincitore, M. M.; Michelini, A. L.; Mayer, R. J.; Fuchs, C. S. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig. Dis. Sci. 2005, 50, 2218-2223.
15. Vallbohmer, D.; Iqbal, S.; Yang, D. Y.; Rhodes, K. E.; Zhang, W.; Gordon, M.; Fazzone, W.; Schultheis, A. M.; Sherrod, A. E.; Danenberg, K. D.; lenz, H.-J. Molecular determinants of irinotecan efficacy. Int. J. Cancer 2006, 119, 2435-2442.
16. Zunino, F.; Pratesi, G. Camptothecins in clinical development. Expert Opin. Invest. Drugs 2004, 13, 269-284.
17. Garcia-Carbonero, R.; Supko, J. G. Current perspective on the clinical experience, pharmacology, and continued development of the camptothecins. Clin. Cancer Res. 2002, 8, 641-661.
18. Kollmannsberger, C.; Mross, K.; Jakob, A.; Kanz, L.; Bokemeyer, C. Topotecan, a novel topoisomerase I inhibitor: pharmacology and clinical experience. Oncology 1999, 56, 1-12. (Pubitemid 29043890)
19. Stewart, D. J. Topotecan in the first-line treatment of small cell lung cancer. Oncologist 2004, 9, 33-42.
20. Markman, M. New, expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist 2007, 12, 186-190. (Pubitemid 46271620)
21. Sugimori, M.; Ejima, A.; Ohsuki, S.; Uoto, K.; Mitsui, I.; Kawato, Y.; Hirota, Y.; Sato, K.; Terasawa, H. Synthesis and antitumor activity of ring A- and F-modified hexacyclic camptothecin analogues. J. Med. Chem. 1998, 41, 2308-2318.
22. Saltz, L. B.; Kemeny, N. E.; Tong, W.; Harrison, J.; Berkery, R.; Kelsen, D. P. 9-Aminocamptothecin by 72 h continuous intravenous infusion is inactive in the treatment of patients with 5-fluorouracil-refractory colorectal carcinoma. Cancer 1997, 80, 1727-1732. (Pubitemid 27475929)
23. Kindler, H. L.; Avadhani, A.; Wade-Oliver, K.; Karrison, T.; Mani, S.; Vokes, E. E. 9-Aminocamptothecin (9-AC) given as a 120 h continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: a phase II trial of the University of Chicago phase II consortium. Invest. New Drugs 2004, 22, 323-327. (Pubitemid 39012572)
24. Bailly, C.; Lanciaux, A.; Dassonneville, L.; Demarquay, D.; Coulomb, H.; Huchet, M.; Lavergne, O.; Bigg, D. C. H. Homocamptothecin, an E-ring-modified camptothecin analogue, generates new topoisomerase I-mediated DNA breaks. Biochemistry 1999, 38, 15556-15563. (Pubitemid 129503597)
25. Lesueur-Ginot, L.; Demarquay, D.; Kiss, R.; Kasprzyk, P. G.; Dassonneville, L.; Bailly, C.; Camara, J.; Lavergne, O.; Bigg, D. C. H. Homocamptothecin, an E-ring-modified camptothecin with enhanced lactone stability, retains topoisomerase I-targeted activity and antitumor properties. Cancer Res. 1999, 59, 2939-2943. (Pubitemid 29283135)
26. Bailly, C.; Laine, W.; Baldeyrou, B.; Huchet, M.; Coulomb, H.; Lanco, C.; Lavergne, O.; Bigg, D. C. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38. Anti-Cancer Drug Des. 2001, 16, 27-36. (Pubitemid 33116832)
27. Lavergne, O.; Lesueur-Ginot, L.; Rodas, Francesc, P.; Kasprzyk, P. G.; Pommier, J.; Demarquay, D.; Prevost, G.; Ulibarri, G.; Rolland, A.; Schiano-Liberatore, A.-M.; Harnett, J.; Pons, D.; Camara, J.; Bigg, D. C. H. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogs. J. Med. Chem. 1998, 41, 5410-5419.
28. Lavergne, O.; Demarquay, D.; Bailly, C.; Lanco, C.; Rolland, A.; Huchet, M.; Coulomb, H.; Muller, N.; Baroggi, N.; Camara, J.; Le Breton, C.; Manginot, E.; Cazaux, J.-B.; Bigg, D. C. H. Topoisomerase I-mediated antiproliferative activity of enantiomerically pure fluorinated homocamptothecins. J. Med. Chem. 2000, 43, 2285-2289.
29. Gelderblom, H.; Salazar, R.; Verweij, J.; Pentheroudakis, G.; de Jonge, M. J. A.; Devlin, M.; van Hooije, C.; Seguy, F.; Obach, R.; Prunonosa, J.; Principe, P.; Twelves, C. Phase I pharmacological and bioavailability study of oral diflomotecan (BN80915), a novel E-ring-modified camptothecin analogue in adults with solid tumors. Clin. Cancer Res. 2003, 9, 4101-4107.
30. Lansiaux, A.; Facompre, M.; Wattez, N.; Hildebrand, M.-P.; Bal, C.; Demarquay, D.; Lavergne, O.; Bigg, D. C. H.; Bailly, C. Apoptosis induced by the homocamptothecin anticancer drug BN80915 in HL- 60 cells. Mol. Pharmacol. 2001, 60, 450-461.
31. Larsen, A. K.; Gilbert, C.; Chyzak, G.; Plisov, S. Y.; Naguibneva, I.; Lavergne, O.; Lesueur-Ginot, L.; Bigg, D. C. H. Unusual potency of BN 80915, a novel fluorinated E-ring modified camptothecin, toward human colon carcinoma cells. Cancer Res. 2001, 61, 2961-2967. (Pubitemid 32691941)
32. Troconiz, I. F.; Garrido, M. J.; Segura, C.; Cendros, J.-M.; Principe, P.; Peraire, C.; Obach, R. Phase I dose-finding study and a pharmacokinetic/ pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours. Cancer Chemother. Pharmacol. 2006, 57, 727-735.
33. Demarquay, D.; Coulomb, H.; Huchet, M.; Lesueur-Ginot, L.; Camara, J.; Lavergne, O.; Bigg, D. C. H. The homocamptothecin, BN 80927, is a potent topoisomerase I poison and topoisomerase II catalytic inhibitor. Ann. N.Y. Acad. Sci. 2000, 922, 301-302.
34. Huchet, M.; Demarquay, D.; Coulomb, H.; Kasprzyk, P.; Carlson, M.; Lauer, J.; Lavergne, O.; Bigg, D. C. H. The dual topoisomerase inhibitor, BN 80927, is highly potent against cell proliferation and tumor growth. Ann. N.Y. Acad. Sci. 2000, 922, 303-305.
35. Lavergne, O.; Harnett, J.; Rolland, A.; Lanco, C.; Lesueur-Ginot, L.; Demarquay, D.; Huchet, M.; Coulomb, H.; Bigg, D. C. H. BN 80927: a novel homocamptothecin with inhibitory activities on both topoisomerase I and topoisomerase II. Bioorg. Med. Chem. Lett. 1999, 9, 2599-2602.
36. Demarquay, D.; Huchet, M.; Coulomb, H.; Lesueur-Ginot, L.; Lavergne, O.; Camara, J.; Kasprzyk, P. G.; Prevost, G.; Bigg, D. C. H. BN80927: A novel homocamptothecin that inhibits proliferation of human tumor cells in vitro and in vivo. Cancer Res. 2004, 64, 4942-4949. (Pubitemid 38924541)
37. Perego, P.; Ciusani, E.; Gatti, L.; Carenini, N.; Corna, E.; Zunino, F. Sensitization to gimatecan-induced apoptosis by tumor necrosis factor-related apoptosis inducing ligand in prostate carcinoma cells. Biochem. Pharmacol. 2006, 71, 791-798.
38. Di Francesco, A. M.; Riccardi, A. S.; Barone, G.; Rutella, S.; Meco, D.; Frapolli, R.; Zucchetti, M.; D'Incalci, M.; Pisano, C.; Carminati, P.; Riccardi, R. The novel lipophilic camptothecin analogue gimatecan is very active in vitro in human neuroblastoma: A comparative study with SN38 and topotecan. Biochem. Pharmacol. 2005, 70, 1125-1136.
39. De Cesare, M.; Pratesi, G.; Veneroni, S.; Bergottini, R.; Zunino, F. Efficacy of the novel camptothecin gimatecan against orthotopic and metastatic human tumor xenograft models. Clin. Cancer Res. 2004, 10, 7357-7364.
40. De Cesare, M.; Pratesi, G.; Perego, P.; Carenini, N.; Tinelli, S.; Merlini, L.; Penco, S.; Pisano, C.; Bucci, F.; Vesci, L.; Pace, S.; Capocasa, F.; Carminati, P.; Zunino, F. Potent antitumor activity and improved pharmacological profile of ST1481, a novel 7-substituted camptothecin. Cancer Res. 2001, 61, 7189-7195. (Pubitemid 32946514)
41. Perego, P.; De Cesare, M.; De Isabella, P.; Carenini, N.; Beggiolin, G.; Pezzoni, G.; Palumbo, M.; Tartaglia, L.; Pratesi, G.; Pisano, C.; Carminati, P.; Scheffer, G. L.; Zunino, F. A novel 7-modified camptothecin analog overcomes breast cancer resistance protein-associated resistance in a mitoxantrone- selected colon carcinoma cell line. Cancer Res. 2001, 61, 6034-6037. (Pubitemid 32762534)
42. Long, B. H.; Balasubramanian, B. N. Non-camptothecin topoisomerase I active compounds as potential anticancer agents. Expert Opin. Ther. Pat. 2000, 10, 635-666.
43. Marchand, C.; Antony, S.; Kohn, K. W.; Cushman, M.; Ioanoviciu, A.; Staker, B. L.; Burgin, A. B.; Stewart, L.; Pommier, Y. A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex. Mol. Cancer Ther. 2006, 5, 287-295.
44. Nagarajan, M.; Morrell, A.; Antony, S.; Kohlhagen, G.; Agama, K.; Pommier, Y.; Ragazzon, P. A.; Garbett, N. C.; Chaires, J. B.; Hollingshead, M.; Cushman, M. Synthesis and Biological Evaluation of Bisindenoisoquinolines as Topoisomerase I Inhibitors. J. Med. Chem. 2006, 49, 5129-5140.
45. Morrell, A.; Antony, S.; Kohlhagen, G.; Pommier, Y.; Cushman, M. A systematic study of nitrated indenoisoquinolines reveals a potent topoisomerase I inhibitor. J. Med. Chem. 2006, 49, 7740-7753.
46. Morrell, A.; Placzek, M. S.; Steffen, J. D.; Antony, S.; Agama, K.; Pommier, Y.; Cushman, M. Investigation of the lactam side chain length necessary for optimal indenoisoquinoline topoisomerase I inhibition and cytotoxicity in human cancer cell cultures. J. Med. Chem. 2007, 50, 2040-2048.
47. Morrell, A.; Placzek, M.; Parmley, S.; Grella, B.; Antony, S.; Pommier, Y.; Cushman, M. Optimization of the indenone ring of indenoisoquinoline topoisomerase I inhibitors. J. Med. Chem. 2007, 50, 4388-4404.
48. Morrell, A.; Placzek, M.; Parmley, S.; Antony, S.; Dexheimer, T. S.; Pommier, Y.; Cushman, M. Nitrated indenoisoquinolines as topoisomerase I inhibitors: a systematic study and optimization. J. Med. Chem. 2007, 50, 4419-4430.
49. Antony, S.; Agama, K. K.; Miao, Z.-H.; Hollingshead, M.; Holbeck, S. L.; Wright, M. H.; Varticovski, L.; Nagarajan, M.; Morrell, A.; Cushman, M.; Pommier, Y. Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H- indeno[1,2-c]isoquinoline)-6-propylamino} propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity. Mol. Pharmacol. 2006, 70, 1109-1120.
50. Saif, M. W.; Diasio, R. B. Edotecarin: a novel topoisomerase I inhibitor. Clin. Colorectal Cancer 2005, 5, 27-36.
51. Long, B. H.; Rose, W. C.; Vyas, D. M.; Matson, J. A.; Forenza, S. Discovery of antitumor indolocarbazoles: rebeccamycin, NSC 655649, and fluoroindolocarbazoles. Curr. Med. Chem.: Anti-Cancer Agents 2002, 2, 255-266.
52. Yamashita, Y.; Fujii, N.; Murakata, C.; Ashizawa, T.; Okabe, M.; Nakano, H. Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives. Biochemistry 1992, 31, 12069-12075. (Pubitemid 23011350)
53. Ohkubo, M.; Kojiri, K.; Kondo, H.; Tanaka, S.; Kawamoto, H.; Nishimura, T.; Nishimura, I.; Yoshinari, T.; Arakawa, H.; Suda, H.; Morishima, H.; Nishimura, S. Synthesis and biological activities of topoisomerase I inhibitors, 6-N-amino analogues of NB-506. Bioorg. Med. Chem. Lett. 1999, 9, 1219-1224.
54. Ohkubo, M.; Nishimura, T.; Kawamoto, H.; Nakano, M.; Honma, T.; Yoshinari, T.; Arakawa, H.; Suda, H.; Morishima, H.; Nishimura, S. Synthesis and biological activities of NB-506 analogues modified at the glucose group. Bioorg. Med. Chem. Lett. 2000, 10, 419-422.
55. Arakawa, H.; Iguchi, T.; Morita, M.; Yoshinari, T.; Kojiri, K.; Suda, H.; Okura, A.; Nishimura, S. Novel indolocarbazole compound 6-N-formylamino-12,13- dihydro-1,11-dihydroxy-13-(β-D-glucopyranosyl)- 5H-indolo[2,3-R]pyrrolo-[3, 4-c]carbazole-5,7(6H)-dione (NB-506): its potent antitumor activities in mice. Cancer Res. 1995, 55, 1316-1320.
56. Yoshinari, T.; Matsumoto, M.; Arakawa, H.; Okada, H.; Noguchi, K.; Suda, H.; Okura, A.; Nishimura, S. Novel antitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13-(β-Dglucopyranosyl) -5H-indolo[2,3-α]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mechanisms of cell line-selective cytotoxicity. Cancer Res. 1995, 55, 1310-1315.
57. Fukasawa, K.; Kimatani, H.; Haya, Y.; Suda, H.; Okura, A.; Nishimura, S.; Yoshinari, T. Sequence-selective DNA cleavage by a topoisomerase I poison, NB-506. Int. J. Cancer 1998, 75, 145-150.
58. Yoshinari, T.; Ohkubo, M.; Fukasawa, K.; Egashira, S.; Haya, Y.; Matsumoto, M.; Nakai, K.; Arakawa, H.; Morishima, H.; Nishimura, S. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res. 1999, 59, 4271-4275. (Pubitemid 29418742)
59. Arakawa, H.; Morita, M.; Kodera, T.; Okura, A.; Ohkubo, M.; Morishima, H.; Nishimura, S. In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn. J. Cancer 1999, 90, 1163-1170.
60. Meng, L.; Liao, Z.; Pommier, Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy. Curr. Top. Med. Chem. 2003, 3, 305-320.
61. Ciomei, M.; Croci, V.; Stellari, F.; Amboldi, N.; Giavarini, R.; Pesenti, E. Antitumor activity of edotecarin in breast carcinoma models. Cancer Chemother. Pharmacol. 2007, 60, 229-235.
62. Ciomei, M.; Croci, V.; Ciavolella, A.; Ballinari, D.; Pesenti, E. Antitumor efficacy of edotecarin as a single agent and in combination with chemotherapy agents in a xenograft model. Clin. Cancer Res. 2006, 12, 2856-2861.
63. Yamada, Y.; Tamura, T.; Yamamoto, N.; Shimoyama, T.; Ueda, Y.; Murakami, H.; Kusaba, H.; Kamiya, Y.; Saka, H.; Tanigawara, Y.; McGovren, J. P.; Natsumeda, Y. Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors. Cancer Chemother. Pharmacol. 2006, 58, 173-182.
64. Hurwitz, H. I.; Cohen, R. B.; McGovren, J. P.; Hirawat, S.; Petros, W. P.; Natsumeda, Y.; Yoshinari, T. A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors. Cancer Chemother. Pharmacol. 2007, 59, 139-147.
65. Queguiner, G.; Pastour, P. Synthesis in the pyridine series. V. Study of the reduction of ethyl pyridinedicarboxylates. Bull. Soc. Chim. Fr. 1969, 10, 3678-3683.
66. Dawson, M. I.; Chan, R.; Hobbs, P. D.; Chao, W.; Schiff, L. J. Aromatic retinoic acid analogs. 2.Synthesis and pharmacological activity. J. Med. Chem. 1983, 26, 1282-1293.
67. Kojima, T.; Hayashi, K.; Iizuka, S.; Tani, F.; Naruta, Y.; Kawano, M.; Ohashi, Y.; Hirai, Y.; Ohkubo, K.; Matsuda, Y.; Fukuzumi, S. Synthesis and characterization of mononuclear ruthenium(III) pyridylamine complexes and mechanistic insights into their catalytic alkane functionalization with m-chloroperbenzoic acid. Chem. - Eur. J. 2007, 13, 8212-8222.
68. Docking study was performed using the Molecular Operating Environment (MOE), Version 2008.10; Chemical Computing Group: Montreal, 2006) suite using 1T8I (PDB ID) as a receptor. During the docking process, a rotamer exploration (implemented in the MOE suite) of all side chains involved in the inhibitor binding was carried out. Among the all possible binding mode generated by the docking study, the most similar one to the experimentally observed binding mode of indrocarbazole scaffold in topoisomerase I mutant (1SEU (PDB ID)) was selected.
69. Staker, B. L.; Feese, M. D.; Cushman, M.; Pommier, Y.; Zembower, D.; Stewart, L.; Burgin, A. B. Structures of three classes of anticancer agents boiund to the human topoisomerase I-DNA covalent complex. J. Med. Chem. 2005, 48, 2336-2345.